Waters Introduces High Resolution Mass Spectrometry Products and Software to Accelerate Drug Development
ASMS 2022 – Waters Corporation (NYSE:WAT) today unveiled new instruments, software and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry (ASMS) 2022 Annual Conference. The products include the new Xevo™ G3 quadrupole time-of-flight (QTof) mass spectrometer, CONFIRM Sequence - a new oligonucleotide sequencing confirmation app for the waters_connect™ software platform and an electrospray ionization source for the high-resolution Waters™ SELECT SERIES™ Multi-Reflecting Time of Flight (MRT) mass spectrometer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220606005253/en/
The new Xevo G3 QTof system is a high-performance, benchtop mass spectrometer for characterizing and quantifying thermally-fragile molecules in applications such as biotherapeutics, forensics, metabolite identification, metabolomics and extractables and leachables. (Photo: Business Wire)
“Innovation in mass spectrometry progresses rapidly. Our product introductions at this year’s ASMS benefit scientists throughout the drug development cycle,” said Jon Pratt, Senior Vice President, Waters Corporation. “For researchers, this means enhanced capability to answer fundamental scientific questions. For the analytical scientist compiling analytical data for new drug filings, it means increased certainty and confidence in knowing precisely what’s in their samples and in what quantities.”
Waters Xevo G3 QTof – A Laboratory Workhorse
The new Xevo G3 QTof system is a high-performance, benchtop mass spectrometer for characterizing and quantifying molecules in applications such as biotherapeutics, forensics, metabolite identification, metabolomics and extractables and leachables. The Xevo G3 QTof system is up to 10X more sensitive than its class-leading predecessor at transmitting thermally fragile molecules and excels at measuring and characterizing denatured or native proteins, peptides and other biotherapeutics.
“Biopharmaceutical development and commercialization requires a deep understanding of product variation, their degradation pathways and the processes that make them,” said Dr. Andrew Mahan, Associate Director, Mass Spectrometry Group Leader, Cell Engineering and Early Development, Janssen. “The extended mass-to-charge ratio (m/z) range of the Xevo G3 QTof is going to be ideal for the analysis of multi-specifics and for native MS analyses.”
Waters engineered the Xevo G3 QTof system to reliably give scientists both reproducible and accurate qualitative and quantitative information about molecules in their samples whether in very small or very large amounts.
New Software App for Confirming Nucleic Acid Sequence of Biotherapeutics
The CONFIRM Sequence app on the waters_connect software platform helps scientists using a Waters LC-MS System to confirm the nucleic acid sequence of therapeutics and identify impurities that could compromise product safety and efficacy.
The CONFIRM Sequence app eliminates 50% of the time it takes for post-processing data review, accelerating characterization and development of nucleic acid therapeutics.iii
The new CONFIRM Sequence app is the first sequencing tool to integrate compliance-ready data acquisition, processing, and reporting - making it ideal for deployment in regulated development and Good Manufacturing Practice (GMP) labs.
Coupling UPLC™ to Waters MRT SELECT SERIES Research Mass Spectrometer with ESI Source for Fast Molecular Characterization
The Waters SELECT SERIES MRT System is now compatible with UPLC-MS with an available electrospray ionization (ESI) source. Coupling the high resolution MRT System with the ESI source enables scientists to accurately resolve and measure low (<200 ppb) concentrations of sample analytes at UPLC acquisition speeds for metabolomics, metabolite identification or peptide mapping applications.
The superior performance of the SELECT SERIES MRT allows scientists to get the highest quality mass spectrometry data and information faster than any commercial mass spectrometer on the market today, giving scientists a much clearer picture of the structure of their molecules at the isotope level iv.
- View Waters ASMS 2022 Online Media Kit for downloadable photos and content
- Download the Waters Xevo G3 QTof brochure
- Download the poster A New Software Tool for Sequence Confirmation and Impurity Analysis of Synthetic Oligonucleotides
- Follow and connect with Waters via LinkedIn, Twitter, and Facebook
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in more than 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters, Xevo, SELECT SERIES, UPLC and waters_connect are trademarks of Waters Corporation.
i Vs. the Waters Xevo G2-XS
ii For thermally-labile compounds
iii Internal estimate based on 30 minutes to review a single oligo sequence data set in CONFIRM Sequence compared to 90 minutes with ThermoFisher’s BioPharma Finder.
iv Waters SELECT SERIES MRT mass resolution >200k FWHM @ m/z 785 and independent of scan time; highest resolution achieved irrespective of scan rate
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Brian J. Murphy
PR Manager, Corporate Communications
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment on the Onset and Worsening of Asthma in Patients With Allergic Rhinitis2.7.2022 16:08:00 EEST | Press release
Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study. Presented at the 2022 European Academy of Allergy and Clinical Immunology (EAACI) congress in Prague (Czech Republic), the real-world study confirmed significant benefit of sublingual liquid allergen immunotherapy treatment (AIT) on the onset and worsening of asthma in patients with allergic rhinitis. The retrospective longitudinal pharmaco-epidemiological real-world study included over 430,000 patients: more than 100,000 patients with allergic rhinitis with or without asthma treated with sublingual liquid immunotherapy and symptomatic drugs; compared to more than 330,000 patients with allergic rhinitis with or without asthma treated with symptomatic drugs only. The primary objective of the study was the evaluation of the impact of sublingual liquid AIT on the onset and worsening of asthma in patients with allergic rhinitis. St
Boyd Acquires Sensata’s Thermal Test and Controls Business1.7.2022 18:29:00 EEST | Press release
Boyd, a world-leading innovator of technologies in engineered materials and thermal management, announced it acquired Sensata’s Thermal Test and Controls Business (NYSE:ST). This business specializes in the design and manufacturing of advanced thermal control systems, adapters, and sockets critical to the thermal test process for high-end logic and memory semiconductors. With a long history of serving leading global semiconductor companies, the addition complements Boyd’s existing thermal business, which includes air and liquid cooled thermal management technologies. Boyd designs and manufactures complex thermal solutions for high-performance semiconductors used in applications such as 5G, hyperscale data center, eMobility, and artificial intelligence. With this acquisition, Boyd expands its offering to current semiconductor customers by adding advanced controls and thermal test systems essential to the production of high-end memory and logic devices. “This acquisition is a natural fit
IFF Completed Divestiture of Microbial Control Business1.7.2022 16:45:00 EEST | Press release
IFF (NYSE:IFF) today announced that it has successfully completed the previously announced divestiture of its Microbial Control business unit to LANXESS. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn. © 2022 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005790/en/ Contact information Michael DeVeau Chief Investor Relatio
Digi International Unveils Digi XBee LR Module for LoRaWAN Connectivity for IoT Deployments1.7.2022 16:00:00 EEST | Press release
Digi International ®, (NASDAQ: DGII), a leading global provider of Internet of Things (IoT) connectivity products, solutions, and services, today unveiled the Digi XBee® LR, the first XBee-class pre-integrated and pre-certified wireless communication module for sensors and end-nodes using LoRaWAN. Coupled with the rich connectivity, device and gateway management capabilities of Digi X-ON™—its Low-Power Wide Area (LPWA) IoT data cloud platform—Digi provides a complete IoT solution with automated provisioning and deployment to help enterprises achieve significant ROI and faster market access. The Digi XBee LR module brings a new connectivity option to one of the most widely adopted wireless IoT module footprints, with more than 20 million devices deployed. This fully developed, tested, and certified module gives OEMs the freedom to create innovative public- or private-cloud solutions for organizations in agriculture, energy, logistics, manufacturing, utilities, and other sectors. These a
Juniper Networks Announces Cloud Metro Innovation to Drive Sustainable Business Growth for Service Providers1.7.2022 15:35:00 EEST | Press release
Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced the innovation that will power its vision and strategy for Cloud Metro – a new category of solutions for service providers, optimized for metro transformation and sustainable business growth. Traditional “retro” metro networks are device-centric and are buckling under the extreme scale, agility and experience demands that widespread digital transformation and the advent of 5G services are bringing. Today’s announcement focuses on enabling sustainable business growth, with a series of high-performance networking systems, powered by AI-enabled, cloud-delivered automation, specifically designed to build next generation Cloud Metro infrastructure. These systems will deliver significantly-reduced natural resource consumption capabilities to help sustain the planet, improved tools and simplified working methods to help sustain over-pressured operations teams, along with embedded service assurance and secur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom